EL7.AI
StocksMedium•4 August 2026•
1 min read

Harmony Biosciences Q2 Revenue Jumps 30% on Strong WAKIX Sales and Pipeline Progress

Key Facts

1WAKIX net revenue grew 30% year-over-year to $261.3 million for the second quarter of 2026.
2The company reiterated its 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.
3Phase 1 SAD data for BP-205 demonstrated favorable safety, tolerability, and pharmacokinetic profiles.

Reflecting strong operational momentum in the biotech sector, Harmony Biosciences reported robust financial results for the second quarter of 2026. Net revenue for its primary drug, WAKIX, grew 30% year-over-year to reach $261.3 million, supported by an increase in the average patient base to 8,950. Consequently, the company reiterated its full-year 2026 revenue guidance for WAKIX, maintaining a target range between $1.0 billion and $1.04 billion.

On the clinical front, the company shared encouraging Phase 1 data for its BP-205 candidate, which demonstrated favorable safety, tolerability, and pharmacokinetic profiles. According to reports, these early-stage results reinforce the company's pipeline strategy in central nervous system indications, complementing the sustained commercial growth of WAKIX during its seventh year on the market.

Looking ahead, investors are monitoring the company's clinical milestones for further validation of its pipeline.